David Mushatt

MSG-01: A Randomized, Double-Blind, Placebo-Controlled Trial of Caspofungin Prophylaxis Followed by Preemptive Therapy for Invasive Candidiasis in High-Risk Adults in the Critical Care Setting

Luis Ostrosky‐Zeichner, Shmuel Shoham, José A. Vázquez et al. · Clinical Infectious Diseases · 2014 · 157 citations · Full text

Pharmacy, Infectious Diseases, Pharmacotherapy +17

Randomized Dose-Ranging Controlled Trial of AQ-13, a Candidate Antimalarial, and Chloroquine in Healthy Volunteers

Fawaz Mzayek, Haiyan Deng, Frances J. Mather et al. · PLoS Clinical Trials · 2007 · 131 citations · Full text

Medicine, Pharmacokinetics, Pharmacology +16

Final Report of the Lyme Disease Review Panel of the Infectious Diseases Society of America

Paul M. Lantos, William A. Charini, Gerald Medoff et al. · Clinical Infectious Diseases · 2010 · 93 citations · Full text

Veterinary Medicine, Infectious Diseases, Epidemiology +9

MSG-10: a Phase 2 study of oral ibrexafungerp (SCY-078) following initial echinocandin therapy in non-neutropenic patients with invasive candidiasis

Andrej Spec, John Pullman, George R. Thompson et al. · Journal of Antimicrobial Chemotherapy · 2019 · 86 citations · Full text

Pharmacy, Pharmacokinetics, Pharmacology +17

Tolerance and Pharmacokinetic Interactions of Rifabutin and Clarithromycin in Human Immunodeficiency Virus-Infected Volunteers

Richard Hafner, James Bethel, Maureen Power et al. · Antimicrobial Agents and Chemotherapy · 1998 · 83 citations · Full text

Pharmacy, Pharmacokinetics, Pharmacology +16